Overview

Pharmacokinetics of Neostigmine and Glycopyrrolate

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
A group of 6 able-bodied healthy volunteers will receive Neostigmine (NEO) and Glycopyrrolate (GLY) intravenously and via 2 methods of Iontophoresis (ION): one-patch and two-patch administration, with subsequent blood draws over 1 hour in order to measure the pharmacokinetic behavior of the drugs in-vivo.
Phase:
Early Phase 1
Details
Lead Sponsor:
James J. Peters Veterans Affairs Medical Center
Treatments:
Glycopyrrolate
Neostigmine